StreetInsider.com News Articles

BMO Capital Starts Perspective Therapeutics Inc (CATX) at Outperform

Wed, 19 Aug 2026 05:33:30 -0400

(Updated - August 19, 2026 5:33 AM EDT)

BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics Inc (NYSE: CATX) with a Outperform rating, PT $11.00.

The analyst comments "We initiate coverage of Perspective Therapeutics with an Outperform rating and an $11 target price. Perspective is developing differentiated precision radioligand therapies using its proprietary lead-212 platform and paired imaging agents. Led by bamzireotide navoxetan in neuroendocrine tumors, its pipeline combines encouraging clinical efficacy & safety with opportunities across melanoma and FAP-expressing solid tumors. Assets could support meaningful differentiation from competitors. Supported by promising clinical, preclinical, and initial human imaging data, we

BMO Capital Starts Perspective Therapeutics Inc (CATX) at Outperform

Wed, 19 Aug 2026 05:33:30 -0400

(Updated - August 19, 2026 5:33 AM EDT)

BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics Inc (NYSE: CATX) with a Outperform rating, PT $11.00.

Perspective Therapeutics Inc (CATX) PT Lowered to $5 at BofA Securities

Fri, 14 Aug 2026 05:18:41 -0400

BofA Securities analyst Alec Stranahan lowered the price target on Perspective Therapeutics Inc (NYSE: CATX) to $5.00 (from $6.00) while maintaining a Neutral rating.

Form SCHEDULE 13G/A Perspective Therapeutics Filed by: MILLENNIUM MANAGEMENT LLC

Thu, 13 Aug 2026 19:59:00 -0400

si-local-file:///var/storage/secattach/20260813/26923168.html

Form SCHEDULE 13G/A Perspective Therapeutics Filed by: MILLENNIUM MANAGEMENT LLC

Thu, 13 Aug 2026 19:59:00 -0400

si-local-file:///var/storage/secattach/20260813/26923168.html

Perspective Therapeutics Inc (CATX) PT Lowered to $14 at Piper Sandler

Tue, 11 Aug 2026 09:55:33 -0400

(Updated - August 11, 2026 9:55 AM EDT)

Piper Sandler analyst Biren Amin lowered the price target on Perspective Therapeutics Inc (NYSE: CATX) to $14.00 (from $16.00) while maintaining an Overweight rating.

The analyst commented: "Next VMT-a-NET Update At ESMO, Ahead Of Pivotal Site Activation By YE26; CATX reported 2Q26 earnings, reaffirming bamzireotide navoxetan's (fka VMT-α-NET) pivotal site activation around YE26 and disclosing the proposed cumulative dose of 20 mCi. Regulatory discussions remain ongoing, and the company has not disclosed whether the ESMO presentation will include additional data from the 2nd half of Cohort 2, as they await full 60 month follow-up

Perspective Therapeutics Inc (CATX) PT Lowered to $14 at Piper Sandler

Tue, 11 Aug 2026 09:55:33 -0400

(Updated - August 11, 2026 9:55 AM EDT)

Piper Sandler analyst Biren Amin lowered the price target on Perspective Therapeutics Inc (NYSE: CATX) to $14.00 (from $16.00) while maintaining an Overweight rating.

Perspective Therapeutics Inc (CATX) PT Lowered to $11 at Truist Securities

Tue, 11 Aug 2026 07:07:36 -0400

Truist Securities analyst Greg Renza lowered the price target on Perspective Therapeutics Inc (NYSE: CATX) to $11.00 (from $12.00) while maintaining a Buy rating.

Perspective Therapeutics, Inc. (CATX) Tops Q2 EPS by 4c

Mon, 10 Aug 2026 17:11:06 -0400

Perspective Therapeutics, Inc. (NYSE: CATX) reported Q2 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $80 thousand versus the consensus estimate of $90.53 thousand.

For earnings history and earnings-related data on Perspective Therapeutics, Inc. (CATX) click here.

Form 10-Q Perspective Therapeutics For: Jun 30

Mon, 10 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260810/26898597.html

Form 10-Q Perspective Therapeutics For: Jun 30

Mon, 10 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260810/26898597.html

Form 8-K Perspective Therapeutics For: Aug 10

Mon, 10 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260810/26898513.html

Form 8-K Perspective Therapeutics For: Aug 10

Mon, 10 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260810/26898513.html

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results

Mon, 10 Aug 2026 16:22:00 -0400

Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback; sufficient isotope access and manufacturing capacity
VMT-α-NET study update accepted for oral presentation at ESMO 2026
VMT01 melanoma and PSV359 FAP-α clinical programs continue to advance
Approximately $237 million in cash, cash equivalents, and short-term investments as of June 30, 2026; expected to be sufficient to fund current planned clinical milestones and operational investments into late 2027